Item request has been placed!
×
Item request cannot be made.
×

Processing Request
Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE
- Publication Information:
Original Publication: [London] : BioMed Central Ltd.
- Subject Terms:
- Abstract:
Background: Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer's disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minimally invasive tools for AD diagnostics. In the present study, the recently developed Multimer Detection System (MDS) for AD, a new enzyme-linked immunosorbent assay for measuring Aβ oligomers selectively, was used to detect Aβ oligomers in the plasma of patients with AD and healthy control individuals.
Methods: Twenty-four patients with AD and 37 cognitively normal control individuals underwent extensive clinical evaluations as follows: blood sampling; detailed neuropsychological tests; brain magnetic resonance imaging; cerebrospinal fluid (CSF) measurement of Aβ42, phosphorylated tau protein (pTau), and total tau protein (tTau); and 11 C-Pittsburgh compound B (PIB) positron emission tomography. Pearson's correlation analyses between the estimations of Aβ oligomer levels by MDS and other conventional AD biomarkers (CSF Aβ 42 , pTau, and tTau, as well as PIB standardized uptake value ratio [PIB SUVR]) were conducted. ROC analyses were used to compare the diagnostic performance of each biomarker.
Results: The plasma levels of Aβ oligomers by MDS were higher in patients with AD than in normal control individuals, and they correlated well with conventional AD biomarkers (levels of Aβ oligomers by MDS vs. CSF Aβ 42 , r = -0.443; PIB SUVR, r = 0.430; CSF pTau, r = 0.530; CSF tTau, r = 0.604). The sensitivity and specificity of detecting plasma Aβ oligomers by MDS for differentiating AD from the normal controls were 78.3% and 86.5%, respectively. The AUC for plasma Aβ oligomers by MDS was 0.844, which was not significantly different from the AUC of other biomarkers (p = 0.250).
Conclusions: Plasma levels of Aβ oligomers could be assessed using MDS, which might be a simple, noninvasive, and accessible assay for evaluating brain amyloid deposition related to AD pathology.
- References:
Neurology. 2009 Mar 24;72(12):1056-61. (PMID: 19307538)
FEBS J. 2010 Mar;277(6):1348-58. (PMID: 20148964)
SAGE Open Med. 2015 Aug 10;3:2050312115598250. (PMID: 26770797)
Biochem Biophys Res Commun. 2012 Jul 13;423(4):697-702. (PMID: 22704931)
Clin Chem. 2005 Feb;51(2):336-45. (PMID: 15563479)
Exp Neurol. 2006 Nov;202(1):125-32. (PMID: 16806179)
Ann Neurol. 2009 Apr;65(4):403-13. (PMID: 19296504)
Alzheimers Res Ther. 2017 Oct 17;9(1):86. (PMID: 29041968)
Neurobiol Aging. 1998 Mar-Apr;19(2):109-16. (PMID: 9558143)
Neurology. 1999 May 12;52(8):1555-62. (PMID: 10331678)
Alzheimers Dement. 2014 Jan;10(1):109-14. (PMID: 24365657)
Brain. 2013 May;136(Pt 5):1383-98. (PMID: 23576130)
J Alzheimers Dis. 2016 May 6;52(4):1403-13. (PMID: 27163824)
Age Ageing. 1994 May;23(3):204-12. (PMID: 8085505)
Biochem Biophys Res Commun. 2010 Feb 19;392(4):505-9. (PMID: 20085753)
J Clin Neurol. 2015 Apr;11(2):132-41. (PMID: 25851891)
Neurobiol Aging. 2010 Mar;31(3):357-67. (PMID: 18486992)
Arch Neurol. 1998 Jul;55(7):937-45. (PMID: 9678311)
Drug Discov Today. 2006 Oct;11(19-20):931-8. (PMID: 16997144)
Biochem Biophys Res Commun. 2000 Feb 24;268(3):750-6. (PMID: 10679277)
J Alzheimers Dis. 2008 Jun;14(2):127-31. (PMID: 18560125)
Arch Neurol. 2009 Feb;66(2):190-9. (PMID: 19204155)
Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
J Neurochem. 2012 Jan;120 Suppl 1:125-39. (PMID: 22121920)
Biochem Biophys Res Commun. 1999 Apr 21;257(3):787-91. (PMID: 10208861)
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10417-22. (PMID: 12925731)
Neurology. 2015 Feb 17;84(7):729-37. (PMID: 25609767)
J Alzheimers Dis. 2010;21(4):1295-301. (PMID: 21504116)
Acta Neuropathol. 2011 Oct;122(4):401-13. (PMID: 21805181)
Arch Neurol. 2012 Oct;69(10):1318-25. (PMID: 22801742)
Int J Nanomedicine. 2015 Sep 09;10 (Spec Iss):241-50. (PMID: 26425091)
Int J Geriatr Psychiatry. 2010 Apr;25(4):403-10. (PMID: 19650161)
- Contributed Indexing:
Keywords: Alzheimer’s disease; Amyloid-β protein; Biomarker; Oligomer
- Accession Number:
0 (2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole)
0 (Amyloid beta-Peptides)
0 (Aniline Compounds)
0 (Benzothiazoles)
0 (Peptide Fragments)
0 (Thiazoles)
0 (amyloid beta-protein (1-42))
0 (tau Proteins)
- Publication Date:
Date Created: 20171217 Date Completed: 20180723 Latest Revision: 20220409
- Publication Date:
20250114
- Accession Number:
PMC5732503
- Accession Number:
10.1186/s13195-017-0324-0
- Accession Number:
29246249
No Comments.